政策与人文

订阅

MedSci主页 / 所有栏目 / 政策与人文

全球临床研究注册机构汇总

2013-06-01 MedSci MedSci原创

临床研究注册
关注

下列所列的机构，均属于ICMJE列表中认可的机构，含中国临床试验注册中心（按拼音字母顺序排列） Australian New Zealand Clinical Trials Registry ClinicalTrials.gov ISRCTN Register

下列所列的机构，均属于ICMJE列表中认可的机构，含中国临床试验注册中心（按拼音字母顺序排列） Australian New Zealand Clinical Trials Registry ClinicalTrials.gov ISRCTN Register UMIN Clinical Trials Registry Nederlands Trial Register Brazilian Clinical Trials Registry (ReBec) Chinese Clinical Trial Registry (ChiCTR) 中国临床试验注册中心 Clinical Research Information Service (CRiS), Republic of Korea Clinical Trials Registry - India (CTRI) Cuban Public Registry of Clinical Trials(RPCEC) EU Clinical Trials Register (EU-CTR) German Clinical Trials Regist

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=13331, encodeId=e1f91333114, content=收藏了，加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70351545376, createdName=125795, createdTime=Sun Dec 21 19:11:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5784, encodeId=3b0f5e845d, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Jun 09 20:06:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556700, encodeId=47ee1556e005d, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Jun 03 13:18:00 CST 2013, time=2013-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5756, encodeId=0c215e56f0, content=太全了，谢谢medsci, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhouyi, createdTime=Sun Jun 02 08:07:00 CST 2013, time=2013-06-02, status=1, ipAttribution=)]
    2014-12-21 125795

    收藏了，加油

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=13331, encodeId=e1f91333114, content=收藏了，加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70351545376, createdName=125795, createdTime=Sun Dec 21 19:11:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5784, encodeId=3b0f5e845d, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Jun 09 20:06:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556700, encodeId=47ee1556e005d, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Jun 03 13:18:00 CST 2013, time=2013-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5756, encodeId=0c215e56f0, content=太全了，谢谢medsci, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhouyi, createdTime=Sun Jun 02 08:07:00 CST 2013, time=2013-06-02, status=1, ipAttribution=)]
    2013-06-09 匿名用户

    不错哦

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=13331, encodeId=e1f91333114, content=收藏了，加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70351545376, createdName=125795, createdTime=Sun Dec 21 19:11:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5784, encodeId=3b0f5e845d, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Jun 09 20:06:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556700, encodeId=47ee1556e005d, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Jun 03 13:18:00 CST 2013, time=2013-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5756, encodeId=0c215e56f0, content=太全了，谢谢medsci, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhouyi, createdTime=Sun Jun 02 08:07:00 CST 2013, time=2013-06-02, status=1, ipAttribution=)]
    2013-06-03 zhyy93

    #注册#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=13331, encodeId=e1f91333114, content=收藏了，加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70351545376, createdName=125795, createdTime=Sun Dec 21 19:11:00 CST 2014, time=2014-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5784, encodeId=3b0f5e845d, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Sun Jun 09 20:06:00 CST 2013, time=2013-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556700, encodeId=47ee1556e005d, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Jun 03 13:18:00 CST 2013, time=2013-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5756, encodeId=0c215e56f0, content=太全了，谢谢medsci, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhouyi, createdTime=Sun Jun 02 08:07:00 CST 2013, time=2013-06-02, status=1, ipAttribution=)]
    2013-06-02 zhouyi

    太全了，谢谢medsci

    0

相关资讯

证实原理试验（PPTs）和验证有效性试验（ETs）的临床试验

证实原理试验（PPTs）和验证有效性试验（ETs）       本次介绍PPTs试验和ETS试验详细内容。PPTs和ETs两大临床研究 类型相对应的两个阶段的临床试验，以支持开展更加灵活、快速和集中的临床研究。采用生物终点、调整后的临床终点、早期使用随机试验、引进适时递进性研究设 计（适用的情况下）等更加符合免疫治疗特点的设计和评价指标，在预

近期NSCLC临床研究进展汇总

    下面汇集了近期有关NSCLC的15个主要的临床研究资料，给大家提供有关NSCLC最近两年来最新的研究进展。从一线治疗的革新，到二线治疗的变化，以及维持治疗的新的曙光。同时，TKI等各类靶向药物展示令人惊奇的疗效，可能给NSCLC治疗带来新的变化。尤其是分子诊断技术给NSCLC带来治疗革命。     先回顾一下早年的研究，2002年

观察性临床研究（病例对照研究）遵循STROBE规范（中文版）

观察性临床研究遵循STROBE规范（中文版）

ASCO 2013：生殖泌尿肿瘤临床研究荟萃

2013年5月31日-6月4日间，美国临床肿瘤学会年会将在芝加哥召开。全球肿瘤医师齐聚一堂，讨论交流一年来肿瘤科的热点、难点和最新进展。此次首先奉上消化肿瘤领域值得关注的临床研究，敬请关注。 前列腺癌 会议报道了前列腺癌治疗领域的两项重大进步，它们可以在维持患者生活质量的同时大幅改善疾病结局。COU-AA- 301的结果得到扩展，阿比特龙的化疗后使用方案得到批准，这一随机、安慰剂对照3期COU

辉瑞中止旗下淋巴瘤药物Inotuzumab的后期临床研究

辉瑞虽然最近有三款癌症药物连续获得批准，但它也遇到了挫折，公司于5月20日声称正在停止一款用于治疗侵袭性非霍奇金淋巴瘤药物的一项后期临床试验，因为独立监督员发现这款药物可能无法改善患者的生存期。辉瑞表示将继续在其它血液癌症方面对这款名为Inotuzumab ozogamicin的试验药物进行研究。 辉瑞肿瘤学业务单元负责临床开发和医疗事务的高级副总裁Mace Rothenberg在一项声明中说：

临床研究：不断犯错，最终接受事实的过程

    常看新闻的人都知道，大众媒体几乎天天都在报道“科学发现”。它们出现在新闻播报和时事评论里，通常是被用来提出各种涉及健康、养育子女、教育乃至信仰、自我认识等重要事情的观点。我们该如何对待它们呢？     举例来说，至少从2004年起我们就一直听到各种有关“维生素D可以预防风湿” 的研究。一份2010年约翰霍普金斯大学健康通告